Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG -1.48%48 Days Sales Outstanding is 32.97 as of Dec. 2025, which is 32% below its 10-year median of 48.63. GuruFocus rates FRA:REG with a GF Score™ of 48/100 and a GF Value™ of €25.42 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, RemeGen Co ranks better than 53.51% on this metric.
RemeGen Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was €47 Mil. RemeGen Co's Revenue for the
six
months ended in Dec. 2025 was €261 Mil.
Hence, RemeGen Co's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 32.97.
The historical rank and industry rank for RemeGen Co's Days Sales Outstanding or its related term are showing as below:
FRA:REG'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.59 Med: 48.63 Max: 85.46
Current: 63.16
During the past 8 years, RemeGen Co's highest Days Sales Outstanding was 85.46. The lowest was 0.59. And the median was 48.63.
FRA:REG's Days Sales Outstanding is ranked better than 53.51% of 841
companies
in the Biotechnology industry
Industry Median: 68.94
vs FRA:REG: 63.16
RemeGen Co's Days Sales Outstanding
declined
from Dec. 2024 (64.31) to Dec. 2025 (32.97).
RemeGen Co (FRA:REG) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
RemeGen Co Days Sales Outstanding Related Terms
RemeGen Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, RemeGen Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Days Sales Outstanding of 32.97 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on RemeGen Co and its competitors. This is 32% below median its historical median of 48.63. Over the past decade, RemeGen Co's Days Sales Outstanding has ranged from 0.59 to 85.46. According to the industry distribution chart, RemeGen Co ranks #391 out of 841 companies in the Biotechnology industry, placing it in the top 46.5%.
Is RemeGen Co's Days Sales Outstanding too high?
RemeGen Co's current Days Sales Outstanding of 32.97 is 32% below median its 10-year median of 48.63. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 85.46. The Biotechnology industry median Days Sales Outstanding is 68.94. RemeGen Co's value of 32.97 is 52.2% below this industry median. Based on the distribution chart, RemeGen Co ranks #391 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #391 out of 841 companies for Days Sales Outstanding. This puts RemeGen Co in the upper half of its industry. The industry median Days Sales Outstanding is 68.94. RemeGen Co's value of 32.97 is 52.2% below this benchmark. Historically, RemeGen Co's own Days Sales Outstanding has ranged from 0.59 to 85.46 over the past decade. While the company's 10-year median is 48.63 vs. the industry median of 68.94, RemeGen Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Days Sales Outstanding of 32.97 is 52.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Days Sales Outstanding is 32.97, which is 32% below median its own 10-year median of 48.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €25.42, compared to a current price of €8.00 — trading 68.5% below its estimated fair value. The current Days Sales Outstanding is 32.97, which is 32% below median its 10-year median of 48.63 and 52.2% below the Biotechnology industry median of 68.94. RemeGen Co's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Days Sales Outstanding is 32.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.00 is trading 68.5% below its estimated GF Value™ of €25.42.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Days Sales Outstanding: 32.97 (32% below median its 10-year median of 48.63)
GF Value™: €25.42 vs. price of €8.00 (68.5% below fair value)
Industry Position: 52.2% below the Biotechnology median (#391 of 841)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
48GF Score
Get the complete analysis for FRA:REG
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
